ELOX — Eloxx Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1035354 ·
Last close
$11.74
Market Cap
$40.34M
52W High
$23.40
52W Low
$8.20
ADV30
24,466
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -4,450,000 -4,502,000 63,388,000 61,960,000 16,968,000
Mar 2026 0 — -3,795,000 -3,754,000 8,503,000 6,363,000 16,087,000
Jun 2025 0 — -1,582,000 -1,891,000 — — —
Mar 2025 0 — -1,222,000 -1,709,000 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,791,000
Investing CF
—
Financing CF
$68,427,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.94
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-308,836,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,028,000
Pretax Income TTM
$-11,856,000
Interest Exp TTM
$828,000
Analysts
4

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -6,438,000 -5,995,000 5,270,000 17,177,000 -11,907,000 -6,327,000
Dec 2024 6,359,000 -2,468,000 -3,143,000 2,976,000 27,311,000 -24,335,000 -4,715,000
Dec 2023 0 -17,288,000 -17,054,000 1,712,000 24,311,000 -22,599,000 -14,341,000
Dec 2022 0 -34,419,000 -36,065,000 21,123,000 31,783,000 -10,660,000 -31,845,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$63,388,000
Forward EPS
$-0.71

Peers — same industry

TickerNameMarket CapLastDaily %
ELUT ELUTIA INC. $37.91M $0.85 —
TVGN Tevogen Inc. $37.05M $5.69 —
CRBU Caribou Biosciences, Inc. $36.81M $0.34 —
TIL Instil Bio, Inc. $36.62M $5.40 —
BKHA Black Hawk Acquisition Corp $35.93M $8.65 —

News headlines (Yahoo Finance, 1h cache)

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
2026-11-18 21:05 · Yahoo
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 12:00 · Yahoo
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
2026-11-02 21:15 · Yahoo
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
2026-10-29 12:00 · Yahoo
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
2026-10-20 13:31 · Yahoo
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
2026-10-19 20:05 · Yahoo
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
2026-09-11 11:30 · Yahoo
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-12 10:00 · Yahoo
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
2026-06-09 01:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.